Diabetes and schizophrenia – effect of disease or drug? Results from a randomized, double‐blind, controlled prospective study in first‐episode schizophrenia

Acta Psychiatrica Scandinavica - Tập 117 Số 5 - Trang 342-347 - 2008
Sahoo Saddichha1, Shahul Ameen2, Sayeed Akhtar3
1National Tobacco Control Program, WHO India, Bhubaneswar
2St. John’s Hospital, Idukki, Kerala, India
3Central Institute of Psychiatry, Ranchi, Jharkhand

Tóm tắt

Objective:  There have been innumerable advances in the pharmacotherapy of schizophrenia, but problems have emerged hand‐in‐glove, such as the presence of treatment‐emergent glucose intolerance and frank diabetes mellitus (DM).Method:  Medication‐naïve patients with schizophrenia (n = 99) underwent baseline fasting and 2 h post‐prandial plasma glucose measurements repeated after 6 weeks after randomization to receive olanzapine, risperidone or haloperidol. The results were compared with a matched healthy control group.Results:  A significant difference (P = 0.002) in baseline 2 h post‐prandial blood sugar (PPBS) was noted between the control group and the treatment group along with a significant increase in weight (P < 0.001), fasting blood sugar (P = 0.01) and 2 h PPBS (P < 0.001) from baseline to endpoint between the groups. A statistical significance in the incidence of DM at endpoint by the WHO criteria (10.1%) was also noted.Conclusion:  Male patients with schizophrenia are liable to develop DM. Antipsychotic treatment leads to the development of DM in a significant 10.1% within 6 weeks.

Từ khóa


Tài liệu tham khảo

10.1016/j.schres.2004.03.024

10.1016/S0924-9338(05)80189-0

10.1016/j.euroneuro.2006.06.003

10.1080/10401230600801234

Kwong K, Higher incidence of diabetes mellitus during exposure to antipsychotics: findings from a retrospective study in the US

Newcomer JW, 2005, Second‐generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review, CNS Drugs, 19, 1

10.1016/S0924-9338(05)80190-7

10.1192/bjp.184.47.s80

10.1016/S0920-9964(99)00191-7

10.1001/jama.283.4.506

10.2165/00023210-200216020-00001

10.1177/070674370304800512

10.1016/S0010-440X(96)90054-1

10.1001/archneurpsyc.1946.02300180084007

Langfeldt G, 1952, The insulin tolerance test in mental disorders, Acta Psychiatr Scand, 80, 189

10.1192/bjp.184.47.s64

10.1192/bjp.184.47.s67

Ryan MCM, 2003, Impaired fasting glucose and elevation of cortisol in drug‐naïve first‐episode schizophrenia, Am J Psychiatry, 160, 284, 10.1176/appi.ajp.160.2.284

10.1016/S0140-6736(89)91392-5

10.1192/bjp.184.47.s72

10.1192/bjp.184.47.s102

10.1517/14740338.5.1.157

10.1016/j.jad.2006.08.009

Sowell M, 2003, Risk factors for diabetes during clinical trials of antipsychotics, J Psychopharmacol, 17, A53

10.1176/appi.ajp.160.2.290

Food and Drug Administration, 2003, Abilify (Aripiprazole) tablets. Center for Drug Evaluation and Research, new and generic drug approvals: 1998–2003

10.1038/sj.npp.1300157

10.1056/NEJMoa051688

Methods in human nutritional assessment – estimating daily energy requirements

10.2337/diacare.20.7.1183

World Health Organization, 1999, Report of a WHO consultation: definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus

World Medical Association, 2000, Declaration of Helsinki. Ethical principles for medical research involving human subjects

10.1016/S0024-3205(02)01646-6

10.1111/j.1600-0447.2006.00784.x

10.1111/j.1600-0447.2005.00700.x

10.1016/j.schres.2005.12.855

Kurpad SS, 2001, Prevalence of obesity among psychiatrically ill patients, Ind J Psychiatry, 43, 125

Sanyal D, 1998, Relationship between lower serum cholesterol level and psychiatric disorders, Ind J Psych, 40, 212

10.2337/diacare.26.5.1380

Thông tin
Thông tin xuất bản

Acta Psychiatrica Scandinavica

Tập 117 Số 5

342-347

Thông tin tác giả